BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 8576796)

  • 1. Effects of angiotensin converting enzyme inhibitors on the progression of diabetic nephropathy.
    Ruilope LM
    J Hypertens Suppl; 1995 Aug; 13(2):S91-3. PubMed ID: 8576796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal protection and antihypertensive drugs: current status.
    Salvetti A; Mattei P; Sudano I
    Drugs; 1999 May; 57(5):665-93. PubMed ID: 10353294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ACE inhibitors or ARBs for diabetic nephropathy: the unrelenting debate.
    Kota SK; Meher LK; Jammula S; Kota SK; Modi KD
    Diabetes Metab Syndr; 2012; 6(4):215-7. PubMed ID: 23199543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retarding the progression of diabetic nephropathy in type 2 diabetes mellitus: focus on hypertension and proteinuria.
    Lee GS
    Ann Acad Med Singap; 2005 Jan; 34(1):24-30. PubMed ID: 15726216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic management of diabetic nephropathy.
    Vivian EM; Rubinstein GB
    Clin Ther; 2002 Nov; 24(11):1741-56; discussion 1719. PubMed ID: 12501871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihypertensive drugs and diabetic nephropathy.
    Mehler PS; Schrier RW
    Curr Hypertens Rep; 1999; 1(2):170-7. PubMed ID: 10981062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of beta-blockade and angiotensin converting enzyme inhibition on kidney function in diabetic nephropathy.
    Hommel E
    J Hypertens Suppl; 1989 Sep; 7(7):S49-51. PubMed ID: 2575661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
    Crook ED; Preddie DC
    Ethn Dis; 2002; 12(4):S3-49-52. PubMed ID: 12477155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Renoprotective effects of ACE inhibitors and AT1 antagonists on diabetic nephropathy beyond blood pressure control].
    Shionoiri H; Yasuda G; Takizawa T; Shionoiri F
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():394-9. PubMed ID: 15999741
    [No Abstract]   [Full Text] [Related]  

  • 12. Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?
    Sternlicht H; Bakris GL
    Blood Purif; 2016; 41(1-3):139-43. PubMed ID: 26766168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy.
    Suzuki H; Kanno Y; Nakamoto H; Okada H; Sugahara S
    Clin Exp Hypertens; 2005; 27(2-3):129-38. PubMed ID: 15835375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural history of early diabetic nephropathy: what are the effects of therapeutic intervention? Melbourne Diabetic Nephropathy Study Group.
    Jerums G; Allen TJ; Gilbert RE; Hammond J; Cooper ME; Campbell DJ; Raffaele J
    J Diabetes Complications; 1995; 9(4):308-14. PubMed ID: 8573754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of blood glucose and blood pressure control on progression of diabetic nephropathy].
    Schwarz C; Oberbauer R
    Wien Klin Wochenschr; 2000 Nov; 112(21):907-11. PubMed ID: 11144004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in pharmacological management of hypertension in diabetic patients with nephropathy. Effects of antihypertensive drugs on kidney function and insulin sensitivity.
    Baba T; Ishizaki T
    Drugs; 1992 Apr; 43(4):464-89. PubMed ID: 1377114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolving strategies for renoprotection: diabetic nephropathy.
    Parving HH; Hovind P; Rossing K; Andersen S
    Curr Opin Nephrol Hypertens; 2001 Jul; 10(4):515-22. PubMed ID: 11458033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The role of ramipril in the therapy of diabetic nephropathy].
    Dézsi CA
    Orv Hetil; 2014 Feb; 155(7):263-9. PubMed ID: 24509355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
    Zanella MT; Ribeiro AB
    Clin Ther; 2002 Jul; 24(7):1019-34. PubMed ID: 12182249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients.
    Yokoyama H; Tomonaga O; Hirayama M; Ishii A; Takeda M; Babazono T; Ujihara U; Takahashi C; Omori Y
    Diabetologia; 1997 Apr; 40(4):405-11. PubMed ID: 9112017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.